Business UpdateMay 6, 2026, 08:27 AM
InflaRx focuses izicopan development on AAV & renal diseases; funds through 2029
AI Summary
InflaRx N.V. announced a strategic shift to focus on developing izicopan, an oral C5aR inhibitor, for ANCA-associated vasculitis (AAV) and a broader range of complement-mediated life-threatening kidney diseases, including aHUS, IgAN, and C3G. The company is conducting Phase 2 planning for AAV and expects to begin open-label studies for other renal indications next year. InflaRx also stated it has sufficient funds for planned clinical development activities and ongoing operations through 2029, and will host a Capital Markets Day in summer 2026 to further detail izicopan's potential.
Key Highlights
- InflaRx to develop izicopan in ANCA-associated vasculitis (AAV) and broader renal disorders.
- Phase 2 planning for izicopan in AAV is underway, exploring expedited market paths.
- Open-label studies for aHUS, IgAN, and C3G expected to generate clinical data next year.
- Company estimates sufficient funds for planned clinical development and operations through 2029.
- Izicopan for hidradenitis suppurativa (HS) development to proceed only with a partner, with a market potential exceeding $1.5 billion per year.
- Capital Markets Day planned for summer 2026 to detail izicopan's potential.
- Webcast to discuss new strategy on Friday, May 8, at 8:30 AM ET / 2:30 PM CET.
Price Impact
More from IFRX